Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
OptimizeRx Management
Management Kriterienprüfungen 2/4
OptimizeRx's CEO is Will Febbo, appointed in Feb 2016, has a tenure of 8.25 years. total yearly compensation is $2.79M, comprised of 16.1% salary and 83.9% bonuses, including company stock and options. directly owns 2.62% of the company’s shares, worth $6.19M. The average tenure of the management team and the board of directors is 3 years and 6.8 years respectively.
Wichtige Informationen
Will Febbo
Geschäftsführender
US$2.8m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 16.1% |
| Amtszeit als Geschäftsführer | 8.3yrs |
| Eigentum des Geschäftsführers | 2.6% |
| Durchschnittliche Amtszeit des Managements | 3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6.8yrs |
Jüngste Management Updates
Recent updates
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09
Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business
Nov 16Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All
Aug 13A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Jul 15Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation
Jun 24Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist
May 10Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Mar 29Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)
Feb 21What Percentage Of OptimizeRx Corporation (NASDAQ:OPRX) Shares Do Insiders Own?
Jan 27
Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | US$3m | US$450k | -US$18m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$694k | US$450k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$3m |
| Dec 31 2021 | US$15m | US$410k | US$378k |
| Sep 30 2021 | n/a | n/a | US$1m |
| Jun 30 2021 | n/a | n/a | US$789k |
| Mar 31 2021 | n/a | n/a | -US$641k |
| Dec 31 2020 | US$1m | US$350k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$6m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$834k | US$300k | -US$3m |
| Sep 30 2019 | n/a | n/a | -US$1m |
| Jun 30 2019 | n/a | n/a | US$548k |
| Mar 31 2019 | n/a | n/a | US$422k |
| Dec 31 2018 | US$923k | US$275k | US$226k |
| Sep 30 2018 | n/a | n/a | US$99k |
| Jun 30 2018 | n/a | n/a | -US$769k |
| Mar 31 2018 | n/a | n/a | -US$1m |
| Dec 31 2017 | US$422k | US$250k | -US$2m |
Vergütung im Vergleich zum Markt: WillDie Gesamtvergütung ($USD2.79M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.63M).
Entschädigung vs. Einkommen: WillDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Will Febbo (54 yo)
8.3yrs
Amtszeit
US$2,789,528
Vergütung
Mr. William J. Febbo, also known as Will, is a Director at LifeMD, Inc. since June 2023. He serves as an Independent Director at Augmedix, Inc. since March 28, 2022. He served as an Independent Director of...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 8.3yrs | US$2.79m | 2.62% $ 6.2m | |
| President | 1.3yrs | US$970.36k | 0.40% $ 942.6k | |
| CFO & COO | 2.6yrs | US$929.73k | 0.11% $ 248.4k | |
| Senior Vice President of Corporate Finance | 2.7yrs | keine Daten | keine Daten | |
| General Counsel & Chief Compliance Officer | 3.3yrs | US$2.51m | 0.078% $ 184.1k | |
| Media Relations Manager | no data | keine Daten | keine Daten | |
| Human Resources Manager | 4.4yrs | keine Daten | keine Daten | |
| Senior Vice President of Pharma | 4.2yrs | US$511.63k | keine Daten | |
| Chief Product Officer | 1.6yrs | keine Daten | 0.021% $ 49.8k | |
| Chief Commercial Officer | less than a year | keine Daten | 0.10% $ 239.6k | |
| Controller | 5.6yrs | keine Daten | keine Daten |
3.0yrs
Durchschnittliche Betriebszugehörigkeit
55.5yo
Durchschnittliches Alter
Erfahrenes Management: OPRX's management team is considered experienced (3 years average tenure).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 8yrs | US$2.79m | 2.62% $ 6.2m | |
| Independent Director | 6.2yrs | US$215.01k | 0.12% $ 286.2k | |
| Independent Director | less than a year | keine Daten | keine Daten | |
| Director | 9.8yrs | US$249.01k | 0.39% $ 917.0k | |
| Independent Director | 3.8yrs | US$195.01k | 0.13% $ 310.1k | |
| Independent Chairperson of the Board | 8.7yrs | US$208.01k | 0.22% $ 510.2k | |
| Head of Medical Advisory Board | 6.2yrs | US$112.91k | keine Daten | |
| Independent Director | 7.3yrs | US$204.01k | 0.24% $ 578.4k |
6.8yrs
Durchschnittliche Betriebszugehörigkeit
65.5yo
Durchschnittliches Alter
Erfahrener Vorstand: OPRX's board of directors are considered experienced (6.8 years average tenure).